Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

<i>Aim and Objectives</i>: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SVR) after DAA treatment are expe...

Full description

Bibliographic Details
Main Authors: Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Medicina
Subjects:
hepatitis C
antiviral agents
sustained virologic response
hepatocellular carcinoma
liver cirrhosis
Online Access:https://www.mdpi.com/1648-9144/59/8/1436

Internet

https://www.mdpi.com/1648-9144/59/8/1436

Similar Items